BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12036890)

  • 1. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
    Million RP; Aster J; Gilliland DG; Van Etten RA
    Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
    Million RP; Van Etten RA
    Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
    Million RP; Harakawa N; Roumiantsev S; Varticovski L; Van Etten RA
    Mol Cell Biol; 2004 Jun; 24(11):4685-95. PubMed ID: 15143164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
    Gross AW; Zhang X; Ren R
    Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion.
    Andreasson P; Johansson B; Carlsson M; Jarlsfelt I; Fioretos T; Mitelman F; Höglund M
    Genes Chromosomes Cancer; 1997 Nov; 20(3):299-304. PubMed ID: 9365838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
    Zhang X; Wong R; Hao SX; Pear WS; Ren R
    Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Hao SX; Ren R
    Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion.
    Tirado CA; Sebastian S; Moore JO; Gong JZ; Goodman BK
    Cancer Genet Cytogenet; 2005 Feb; 157(1):74-7. PubMed ID: 15676152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
    Yokota A; Hirai H; Shoji T; Maekawa T; Okuda K
    Leukemia; 2017 Dec; 31(12):2742-2751. PubMed ID: 28386107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia.
    Inokuchi K; Shinohara T; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Nomura T; Dan K
    Genes Chromosomes Cancer; 1998 Nov; 23(3):227-38. PubMed ID: 9790503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
    Gustafsson K; Jamalpour M; Trinh C; Kharas MG; Welsh M
    J Hematol Oncol; 2014 Jun; 7():45. PubMed ID: 24952416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
    Peeters P; Raynaud SD; Cools J; Wlodarska I; Grosgeorge J; Philip P; Monpoux F; Van Rompaey L; Baens M; Van den Berghe H; Marynen P
    Blood; 1997 Oct; 90(7):2535-40. PubMed ID: 9326218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM; Ren R
    Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.